OncoSec Medical News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.05.19	5 Top Losers In Pharma Sector (BCRX, ONCS, OCUL...) (RTTNews)
07.11.18	ONCS Hits New Low, AAC Trims Revenue Outlook, NVRO Down 45% YTD (RTTNews)
23.10.18	PETX On The Move, TTOO To Report Q3 Results On Nov.1, CLGN Inks Deal With UTHR (RTTNews)
08.06.18	Impartner Continues Rapid Expansion of Channel Management Technology Portfolio with Announcement of New Acquisition (PR Newswire)
04.06.18	OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting (PR Newswire)
01.06.18	Southwest Gas Holdings, Inc. Announces Filing of Nevada General Rate Case and Approval of Mesquite Expansion (PR Newswire)
24.05.18	Alicia Silverstone, Dave Asprey, angel Kyodo williams, Sally Kohn and more added to Wanderlust's Wellspring Conference (PR Newswire)
08.05.18	OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer (PR Newswire)
03.05.18	OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference (PR Newswire)
26.04.18	OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting (PR Newswire)
16.04.18	OncoSec Provides Highlights from Research Reception at AACR Annual Meeting 2018 (PR Newswire)
03.04.18	OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting (PR Newswire)
20.03.18	OncoSec Announces Strategic Relocation Of Office And Laboratories (PR Newswire)
16.03.18	OncoSec To Present At The Oppenheimer's 28th Annual Healthcare Conference (PR Newswire)
15.03.18	OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018 (PR Newswire)
12.03.18	OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer (PR Newswire)
12.03.18	EPIC's Chuck Simpson to Present on Hazard Recognition at Arklatex ASSE Chapter Meeting (PR Newswire)
16.01.18	OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors (PR Newswire)
08.01.18	Royole to Introduce Smart Writing Pad at CES 2018 (PR Newswire)
03.01.18	OncoSec Provides 2018 Business Outlook (PR Newswire)
14.12.17	OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab (PR Newswire)
05.12.17	OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer (PR Newswire)
28.11.17	OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform (PR Newswire)
14.11.17	FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz (RTTNews)
13.11.17	OncoSec Receives $9.3 Million Warrant Exercise (PR Newswire)
09.11.17	OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 (PR Newswire)
08.11.17	OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at... (PR Newswire)
07.11.17	OncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company (PR Newswire)
25.10.17	OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017 (PR Newswire)
19.10.17	OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder... (PR Newswire)
13.10.17	OncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017 (PR Newswire)
12.10.17	OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse® IL-12 at the 9th World Congress of Melanoma - A Joint Meeting... (PR Newswire)
11.10.17	OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 (PR Newswire)
10.10.17	OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck's KEYTRUDA® (pembrolizumab) (PR Newswire)
04.10.17	EPIC adds Broker/Producer Tim House in Fresno (PR Newswire)
27.09.17	OncoSec Presents Clinical Overview of Comprehensive Immune Monitoring Data Demonstrating Conversion of "Cold" Tumors to "Hot" Tumors with ImmunoPulse® IL-12 and Pembrolizumab Combination Therapy (PR Newswire)
26.09.17	OncoSec to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire)
06.09.17	OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences (PR Newswire)
05.09.17	OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors (PR Newswire)
19.06.17	MVP American Securities Promotes Brandon Welch to Managing Director, Capital Markets (PR Newswire)
12.06.17	OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc. (PR Newswire)
09.06.17	D-Day For CHRS, ENDO Pained, FDA Lifts Clinical Hold On INO's VGX-3100 Trial (RTTNews)
16.05.17	Gainers & Losers Of May 15: CBMG, ETRM, ALNY, EGRX, ONCS... (RTTNews)
11.05.17	OncoSec to Host Third Quarter Financial Conference Call on June 1, 2017 (PR Newswire)
10.05.17	OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma (PR Newswire)
02.05.17	OncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017 (PR Newswire)
02.05.17	How These Biotech Stocks are Faring? -- ContraVir Pharma, Intra-Cellular Therapies, Nivalis Therapeutics, and OncoSec Medical (PR Newswire)
03.04.17	OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting (PR Newswire)
28.03.17	OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017 (PR Newswire)
23.03.17	Innovative Immunotherapies Emerging as the Cancer Treatments of the Future (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu OncoSec Medical Inc

Aktien Top/Flop

Meistgelesene Nachrichten